ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant) [Yahoo! Finance]
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.